Completed

TOPRed Blood Cell Transfusion Strategies for Extremely Low Birth Weight Infants

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to evaluate different red blood cell transfusion strategies to understand their impact on the risk of cognitive delay, death, and neurodevelopmental impairment in extremely low birth weight infants.

What is being tested

Restricted red cell transfusion

+ Liberal Cell Transfusion

Procedure
Who is being recruted

Hematologic Diseases+8

+ Hemic and Lymphatic Diseases

+ Infant, Premature, Diseases

+16 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: December 2012
See protocol details

Summary

Principal SponsorNICHD Neonatal Research Network
Last updated: November 14, 2025
Sourced from a government-validated database.Claim as a partner

Study start date: December 1, 2012

Actual date on which the first participant was enrolled.

Long-term outcomes of extremely low birth weight (ELBW) preterm infants, those weighing less than or equal to 1000 g at birth, are poor and pose a major health care burden. Virtually all of these infants are transfused, but at inconsistent hemoglobin (Hgb) thresholds. The investigators propose in TOP to randomize infants less than or equal to 1000 g BW and gestational age at least 22 weeks but less than 29 weeks to receive red blood cell (RBC) transfusions according to one of two strategies of Hgb thresholds, either a high Hgb (liberal transfusion) or a low Hgb (restrictive transfusion) algorithm. It is currently unknown which transfusion strategy is superior. TOP is powered to demonstrate which strategy reduces the primary outcome of death or neurodisability in survivors at 22-26 months. A secondary study entitled "Effect of Blood Transfusion Practices on Cerebral and Somatic Oximetry", also known as the NIRS study, will determine differences in cerebral oxygenation and fractional tissue oxygen extraction with NIRS between high and low hemoglobin threshold groups during red blood cell transfusions. The investigators also propose to determine whether abnormal cerebral NIRS measures are a better predictor of NDI than hemoglobin alone and whether abnormal mesenteric NIRS measures are associated with the development of NEC within the 48 hours following a transfusion. A secondary study entitled "Economic Evaluation Ancillary to the Transfusion of Prematures Randomized Controlled Trial" will determine whether higher transfusion threshold will result in lower total costs to society over the first 22 to 26 corrected months of life and estimate the incremental cost-effectiveness ratio for survival without neurodevelopmental impairment, from the perspective of society, the third-party payer, and the family. Extended follow-up: Subjects will be seen for a follow-up visit at 5-6 years corrected age to assess neurological and functional outcomes at early school age based on neonatal transfusion threshold.

NCT01702805
Principal SponsorNICHD Neonatal Research Network
Last updated: November 14, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

1824 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Hematologic DiseasesHemic and Lymphatic DiseasesInfant, Premature, DiseasesLung DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesRespiratory Tract DiseasesLung InjuryVentilator-Induced Lung InjuryAnemiaBronchopulmonary DysplasiaInfant, Newborn, Diseases

Criteria

3 inclusion criteria required to participate
Admitted to the NICU within 48 hours of life

Birth weight less than or equal to 1000 grams

Gestational age at least 22 weeks but less than 29 weeks

13 exclusion criteria prevent from participating
Congenital condition, other than premature birth, that adversely affects life expectancy or neurodevelopment

Considered nonviable by the attending neonatologist

Cyanotic congenital heart disease

High probability that the family is socially disorganized to the point of being unable to attend follow-up at 22-26 months

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
Transfusions will be administered using a lower threshold hemoglobin value. The low threshold values reflect more common practice, so this is considered the 'usual treatment' group

Group II

Active Comparator
Transfusions will be administered using a higher threshold hemoglobin value.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 20 locations

University of Alabama at Birmingham

Birmingham, United StatesOpen University of Alabama at Birmingham in Google Maps

University of California - Los Angeles

Los Angeles, United States

Stanford University

Palo Alto, United States

Emory University

Atlanta, United States
Completed20 Study Centers